Serono plans multiple sclerosis treatment by inhalation


Serono of Switzerland is planning to expand its billion dollar multiple sclerosis franchise with a new version of interferon beta that would do away with the need for injections, reports Phil Taylor.

The company already sells an injectable drug for MS, Rebif (interferon beta 1a) and has small molecule, orally active drugs in its pipeline. These could now been joined by an inhaleable formulation that would provide a more patient-friendly alternative to the current injectable drugs for MS, and could improve efficacy.

Inhale here.

March 31, 2005 in rebif, research, treatment, worth following... | Permalink | Comments (0)

Serono Completes Patient Enrollment in Rebif(R) Versus Copaxone(R) Comparative Clinical Trial

Serono (virt-x: SEO and NYSE: SRA) announced today that patient enrollment has been completed in a multi-national Rebif(R) (interferon beta-1a) versus Copaxone(R) (glatiramer acetate) comparative clinical trial. This two-year trial is designed to compare the efficacy of the two therapies in patients with relapsing remitting multiple sclerosis (RRMS), who were previously untreated with disease modifying therapies.

More here.

January 5, 2005 in copaxone, rebif, research, worth following... | Permalink | Comments (0)

Central nervous system big money

Central nervous system (CNS) treatments are big business – and are growing at the fastest rate among the largest therapeutic categories. The global sales of CNS therapeutics are second only to those sold for cardiovascular ailments.

One of the fastest growing markets is in treatments for multiple sclerosis, which grew by 21 percent in 2002. Due to a frustrating history of ineffective MS treatments, doctors and patients are embracing these biotech innovations.

Read here.

December 8, 2003 in avonex, economy, follow the money..., rebif, stocks | Permalink | Comments (0)

Serono MS drug's U.S. expansion plan on track-CEO

Europe's biggest biotechnology company is heavily reliant on its MS drug and investors were disappointed with third-quarter U.S. sales. Serono shares have risen by around a fifth this year, closing at 890 Swiss francs on Friday.

Read it here.

December 2, 2003 in economy, follow the money..., rebif, stocks | Permalink | Comments (0)

Clinical Effects of COPAXONE(R) or Interferon Therapy Compared to Untreated RRMS Patients

The percentages of relapse-free patients in each group were: COPAXONE -- 83 percent; Avonex -- 65 percent; Rebif -- 60 percent; Betaseron -- 60 percent; no treatment -- 37 percent.

Adriana Carra, M.D., Department of Neurology, Hospital Britanico de Buenos Aires, Argentina, spoke about the results. "It is clear that immunomodulatory therapy is beneficial in the long-term treatment of relapsing-remitting patients compared to no treatment. Our data are similar to those observed in other studies published or presented."

Read it here.

November 5, 2003 in avonex, betaseron, copaxone, interferon-beta, rebif, research | Permalink | Comments (0)

Serono Posts Strong 3Q On Rebif, Weaker Dollar

"Swiss pharmaceutical company Serono SA Thursday reported a solid rise in third quarter net profit on healthy revenue growth, driven by sales of its key drug Rebif and a weaker dollar."

Read it here.

October 23, 2003 in follow the money..., rebif, stocks | Permalink | Comments (1)